The Predominant Prognostic Significance of NOTCH1 Mutation Defined by Emulsion PCR in Chronic Lymphocytic Leukemia.

PURPOSE: NOTCH1 mut represents a new prognostic marker in chronic lymphocytic leukaemia (CLL). The low sensitivity of the current methods may increase the risk of false-negative results, particularly in patients with low NOTCH1 mut allelic burden. This study compared two methods of the NOTCH1 mut assessment including droplet digital PCR (ddPCR) and amplification-refractory mutation system PCR (ARMS-PCR) untreated CLL patients. PATIENTS AND METHODS: This study included 319 untreated CLL patients. Two PCR-based methods; ddPCR and ARMS-PCR were performed to assess the mutational status of NOTCH1. The Mann-Whitney, Fisher's exact test, Kruskal-Wallis, Kaplan-Meier, Log rank tests and multivariate Cox proportional hazard regression model were used to analyze collected data.
RESULTS: We proved that ddPCR increased the detectability of the NOTCH1 mut compared to ARMS-PCR in CLL (18.55% vs 6%). We showed a shorter time to first treatment (TTFT) in the NOTCH1 mut group of patients compared to the NOTCH1 wt defined by ddPCR (1.5 vs 33 months, p=0.01). The TTFT survival curves analysis in subgroups divided according to the mutational status of IGHV and NOTCH1 assessed by ddPCR discriminated group with the best prognosis: IGHV mut NOTCH1 wt. Multivariate analysis revealed that the mutational status of IGHV represented an independent prognostic factor for TTFT, while NOTCH1 mut determined by ddPCR constituted as a dependent prognostic factor for TTFT.
CONCLUSION: The selection of the precise method of NOTCH1 mut detection as ddPCR might significantly improve prognostic stratification of CLL patient. Assessment of IGHV might be relevant to more accurate discrimination of prognostic groups of CLL patients, especially in harboring NOTCH1 mut irrespective of the quantity of allelic burden.

Introduction

The most important genetic features predicting clinical outcome in chronic lymphocytic leukemia (CLL) include somatic mutations of coding the genes of immunoglobulin heavy chain variable (IGHV) and TP53 gene as well as deletions of the short arm of chromosome 17 (17p-).1 To explain the molecular basis of the high heterogeneity of CLL, new molecular and genomic markers have been recently identified.2–4

So far, the whole genome as well as the exome sequencing identified around 80 recurrently mutated genes in CLL, including genes involved in NOTCH signaling (NOTCH1, NOTCH2, FBXW7).5–7 The most common mutation occurring in more than 90% of all CLL patients with a mutation in NOTCH1 (NOTCH1mut) is a two base-pair frameshift-deletion (c.7541_7542delCT).8 This lesion mainly involves the truncation of the C-terminal PEST (peptide sequence that is rich in proline (P), glutamic acid (E), serine (S) and threonine (T)) domain, which is associated with turnover of NOTCH1 protein preserving the stable activated form of NOTCH1.5,9

The incidence of NOTCH1mut in CLL patients is variable and depends mainly on the detection method ranging from 7% to 22%.8,10–14 In Richter transformation and chemorefractory CLL, the frequency of NOTCH1mut was significantly higher and accounted for up to 20.8% and 31%, respectively.7,8,15–17 Additionally, a higher incidence of this mutation in CLL patients with a trisomy 12 suggests possible functional synergy.18–20 Moreover, NOTCH1mut represented a risk factor of transformation into diffuse large B-cell lymphoma (DLBCL).21 Although NOTCH1mut was found in the most reports to be associated with a worse prognosis of the disease, there are still limited data about the clinical significance of NOTCH1mut allelic burden.10,12,22

In addition to Sanger and NGS sequencing, also methods based on polymerase chain reaction (PCR), including amplification-refractory mutation system (ARMS-PCR) and droplet digital PCR (ddPCR) could be used to detect mutation in the NOTCH1. The ddPCR provides not only qualitative but also quantitative analysis; thus, it might be used to distinguish groups of patients with different NOTCH1mut allelic burden. In ddPCR absolute quantities are measured by counting molecules of nucleic acid reaction encapsulated in volumetrically defined droplets.23 Applications of ddPCR include detection as well as precise and sensitive quantification of low abundance target including rare mutations and gene expression.24,25

The utilization of methods with low sensitivity may increase the incidence of false-negative results especially in patients with low NOTCH1mut allelic burden. Assessment of NOTCH1mut distribution in different biological and clinical subgroups of CLL using ddPCR might determine its correlation with the heterogeneous behavior of the disease. The current study aimed to compare the clinical consequences of the ARMS-PCR and ddPCR methods to assess NOTCH1mut in CLL patients.

Patients and Methods

Characteristics of Patients

The current study involved 319 (193 males, 126 females, median age 65) newly diagnosed and previously untreated CLL patients at Department of Hematology, St. John’s Cancer Centre, Lublin, Department of Hematology, Military Institute of Medicine, Warsaw, as well as Department of Hematooncology and Bone Marrow Transplantation, Lublin. Among a cohort of CLL 319 patients, 300 were included in ARMS-PCR and 248 in ddPCR assessment of NOTCH1mut. In the cohort of 225, both methods were performed. The clinical characteristics of the three cohorts of CLL patients are presented in Table 1. Cytogenetic aberrations were performed in diagnostic laboratory according to their routine procedures.

Table 1

Clinical Characteristic of Patients

	ARMS-PCR n=300	ddPCR n=248	ARMS-PCR + ddPCR n=225
Sex
Male	180	149	134
Female	120	99	91
Age
Median	66	66	66
Range	38–90	38–90	38–90
Rai Stage
0	75	56	50
I	37	37	30
II	52	39	37
III	11	10	8
IV	19	9	9
n/a	106	97	91
ZAP-70 (cut off 20%)
+	84	72	67
–	165	124	115
CD38 (cut off 30%)
+	74	60	58
–	182	144	131
Mutational status of IGHV
Mutated	140	107	106
Unmutated	157	117	116
n/a	3	25	3
Cytogenetic aberrations
Adverse	40	27	26
Intermediate	91	78	76
Favorable	54	46	46
n/a	115	97	77

Notes: Cytogenetic aberration subgroups: adverse (17p‐, 11q‐), intermediate (trisomy 12, normal karyotype, various); favorable (isolated 13q‐).

Abbreviation: n/a, not available data.

Isolation of Mononuclear Cells and DNA

Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation with Biocoll (Biochrom, Berlin, Germany).

DNA was isolated using the Qiamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The quality and quantity of the obtained DNA were quantified spectrophotometrically (OD 260/280) using a BioSpec-nano (Shimadzu, Yoko, Japan).

Amplification-Refractory Mutation System PCR (ARMS-PCR)

For the investigation of NOTCH1mut by ARMS-PCR the Veriti thermal cycler (Thermo Fisher, Waltman, USA) was used. Three starters were used including: 5ʹ-GTGACCGCAGCCCAGTT-3ʹ (forward primer for wild-type); 5ʹTCCTCACCCCGTCCCGA3ʹ (forward primer for mutation); 5ʹ-AAGGCTTGGGAAAGGAAGC-3ʹ (reverse primer for wild-type and mutation). The reaction was conducted in a total volume of 20 µL containing Qiagen Multiplex Master Mix (Qiagen, Hilden, Germany), primers and 200 ng DNA under the following conditions: denaturing step at 95°C for 3 min followed by 30 cycles at 95°C (30 seconds per cycle), annealing step at 57°C (40 seconds per cycle), and extension at 72°C (40 seconds per cycle). Products of PCR reactions were separated in agarose gel during electrophoresis.

Droplet Digital PCR (ddPCR)

For the investigation of NOTCH1 by ddPCR method, the QX200 micro drop reader (Bio-Rad, California, USA) and specific molecular probes were used. The mutation in the NOTCH1 gene was detected using PrimePCR ddPCR Mutation Assay: NOTCH1wt and PrimePCR ddPCR Mutation Assay: NOTCH1mut (Bio-Rad, California, USA), a set of specific molecular probes for the wild-type and mutation. The ddPCR reaction was conducted using 200 ng template DNA in a final volume of 20 μL. PCR reaction was performed under the following conditions: denaturing step at 95°C for 10 min followed by 40 cycles at 95°C (30 seconds per cycle), annealing/extension step at 55°C (60 seconds per cycle). After amplification, the plate was placed into the QX200 microdrop reader (Bio-Rad, California, USA). Afterward, the data were analyzed using the QuantaSoft v1.7.4. Software ().

Cloning of NOTCH1mut Fragment

Genomic DNA isolated from a NOTCH1mut patient was amplified using primers: 5ʹTCCTCACCCCGTCCCGA3ʹ (Fmut primer) and 5ʹ-AAGGCTTGGGAAAGGAAGC-3ʹ Rmut primer). Products were resolved on 1.5% agarose gels by electrophoresis and purified by QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) before performing the cloning reaction. Cloning was conducted with the StrataClone PCR Cloning Kit (Agilent Technologies, Santa Clara, USA) according to the manufacturing protocol. Specific NOTCH1 ARMS-PCR was performed to detect the mutation in positive colonies. Mutation carrying clones were also confirmed by Sanger sequencing. The verified NOTCH1mut insert was used as a template for evaluation of the detection limit ().

Statistical Analysis

All the results are presented as median values for continuous variables and frequency for categorical variables. Data were being considered significant if the p-value was 0.05 or less. To compute the correlations of variables, Spearman’s rank correlation test was used. To evaluate the differences between the continuous variables in subgroups of patients, the Mann–Whitney test was used. To evaluate the differences between the categorical valuables in subgroups of patients, the Kruskal–Wallis test was conducted. Survival curves of CLL patients were calculated for the time to first treatment (TTFT) according to the Kaplan–Meier method using a Log rank test. A Cox proportional-hazards regression was used to define prognostic variables. As quantitative information on the significance of results 95% intervals (95% CI) of hazard ratios (HR) were estimated. Statistical analyses were performed using Graph Pad Prism 5 (Graph Pad Software, USA) and MedCalc (MedCalc Statistical Software, Belgium).

Results

Frequency of the NOTCH1mut Defined by ddPCR Compared to ARMS-PCR

ARMS-PCR analysis of NOTCH1 mutation status was performed in a cohort of 300 CLL patients. Using the ARMS-PCR methodology we found NOTCH1mut in 18/300 (6%) CLL patients. The example of ARMS-PCR analysis for NOTCH1mut detection is presented in data in .

ddPCR analysis of NOTCH1 mutation status was performed in a cohort of 248 CLL patients. The ddPCR analysis determined a higher cohort of CLL patients with NOTCH1mut 46/248 (18.55%). The coexistence of NOTCH1mut detection with both methods was confirmed (p=0.0001) (Figure 1A).

Figure 1

The coexistence of NOTCH1mut detection with ddPCR and ARMS-PCR. (A) The coexistence of NOTCH1mut detection with ddPCR and ARMS-PCR. Fisher’s exact test confirmed the coexistence of NOTCH1mut detection with both methods (p=0.0001). The frequency of CLL patient with NOTCH1mut assessed by ddPCR was higher than ARMS-PCR (18.55% vs 6%). (B) The median NOTCH1mut allelic burden was significantly higher in a group defined as mutated by both ARMS-PCR and ddPCR compared to a group defined as mutated only by ddPCR (39.45 vs 3.27%, p<0.0001).

In a cohort of 225 CLL patients, we performed both ddPCR and ARMS-PCR analysis. In this cohort, ARMS-PCR detected 16/225 (7.1%) patients with NOTCH1mut, while ddPCR revealed 42/225 (18.6%) with NOTCH1mut. We found 26/225 (11.6%) patients with mutation confirmed only by ddPCR, not by ARMS-PCR.

NOTCH1mut Allelic Burden in CLL

NOTCH1mut allelic burden in NOTCH1mut group defined as positive by both ddPCR as well as ARMS-PCR was found to be higher compared to a group of NOTCH1mut group assessed as positive only by ddPCR (39.45 vs 3.27%, p<0.0001) (Figure 1B). The median of NOTCH1mut allelic burden in all CLL patients was 0.016% with the range of 0–67.9%. The median of NOTCH1mut allelic burden in patients with NOTCH1mut was 7.57%.

Association of NOTCH1mut Assessed by ddPCR Compared to ARMS-PCR with Known CLL Prognostic Markers

ARMS-PCR approach showed that NOTCH1mut patients are more often characterized by unmutated (UM) IGHV gene status (n=17/18, 95%, p<0.0001), compared to NOTCH1wt patients. Worthwhile ddPCR analysis indicated the only tendency for a more frequent occurrence of IGHVum in the NOTCH1mut vs NOTCH1wt group (n=26/42, 62%, p=0.17) (Figure 2A and B).

Figure 2

Association of NOTCH1mut assessed by ddPCR compared to ARMS-PCR with known CLL prognostic markers. (A) The contingency between the mutational status of NOTCH1 and IGHV in ddPCR. The ddPCR analysis indicated only a tendency for the more frequent occurrence of unmutated genes (um) for IGHV in the NOTCH1mut vs NOTCH1wt group (n=26/42, 62%, p=0.17). (B) The contingency between the mutational status of NOTCH1 and IGHV in ARMS-PCR. The ARMS-PCR analysis showed that NOTCH1mut patients were more often characterized by IGHVum gene status compared NOTCH1wt patients (n=17/18, 95%, p<0.0001). (C) The CD38 expression was higher in NOTCH1mut group compared to NOTCH1wt defined using ddPCR (24.99 vs 7.48, p<0.01). (D) The ZAP-70 expression was tended to be higher in NOTCH1mut group compared to NOTCH1wt defined by ddPCR (18.03 vs 10.62, p=0.08). (E) The CD38 expression was higher in NOTCH1mut group compared to NOTCH1wt assessed by ARMS-PCR (34.43 vs 7.63, p=0.02). (F) The ZAP-70 expression was higher in NOTCH1mut compared to NOTCH1wt group assessed by ARMS-PCR (24.36 vs 11.18, p=0.03).

The ddPCR analysis of the NOTCH1mut assessment showed higher CD38 expression in the NOTCH1mut than NOTCH1 group of CLL patients (24.99 vs 7.48, p<0.01) (Figure 2C). Moreover, the ddPCR analysis showed a tendency to higher ZAP-70 expression in the NOTCH1mut than NOTCH1wt group of CLL patients (18.03 vs 10.62, p=0.08) (Figure 2D).

Evaluation of NOTCH1mut using ARMS-PCR showed higher expression of CD38 (34.43 vs 7.63, p=0.02) and ZAP-70 (24.36 vs 11.18, p=0.03) in NOTCH1mut compared to NOTCH1wt group, respectively (Figure 2E and F).

In a cohort of 130 CLL patients, the mutational status of both TP53 and NOTCH1 was assessed. There was no association between status of mutation of NOTCH1 and TP53 (p=0.59).

Statistical analysis did not show any associations between NOTCH1 mutational status identified by ddPCR nor by ARMS-PCR and other clinical and biological features, including Rai stage, cytogenetic aberrations and sex.

Prognostic Value of NOTCH1mut Detected by ddPCR vs ARMS-PCR

The analysis of survival curves showed a significantly shorter median TTFT in the NOTCH1mut group of patients compared to the NOTCH1 group assessed by the ddPCR method (1.5 months vs 33 months, p=0.01) (Figure 3A). However, there was no significant difference in TTFT in NOTCH1mut vs NOTCH1wt group of patients determined by ARMS-PCR (p=0.2) (Figure 3B).

Figure 3

Prognostic value of NOTCH1mut identified using ddPCR compared to ARMS-PCR. (A) Time to first treatment (TTFT) divided according to the mutational status of NOTCH1 assessed by ddPCR. The ddPCR analysis showed significantly shorter TTFT in the NOTCH1mut group of patients compared to NOTCH1wt (1.5 months vs 33 months, p=0.01). (B) TTFT divided according to the mutational status of NOTCH1 assessed by ARMS-PCR. No difference was seen in TTFT of NOTCH1mut group of patients compared to NOTCH1wt determined by ARMS-PCR (3.5 months vs 25 months, p=0.2). (C) TTFT divided into three groups according to the mutational status of NOTCH1 identified using ddPCR compared to AMRS-PCR: NOTCH1wt, NOTCH1mut (ddPCR+/ARMS-PCR+), NOTCH1mut (ddPCR+/ARMS-PCR-). TTFT is shorter in cases defined as a positive for the detection NOTCH1mut by both methods: ddPCR and ARMS-PCR compared to those without mutation NOTCH1wt (1 month vs 11 months, p=0.001). TTFT in CLL cases bearing NOTCH1mut defined as mutated only by ddPCR as well as defined as positive by both methods ddPCR and ARMS-PCR was tended to be shorter compared to NOTCH1wt group of CLL (1 month vs 1 month vs 11 months; p=0.09). TTFT between two groups NOTCH1mut detected by ddPCR and not by ARMS-PCR and the NOTCH1wt group was no statistically different (1 month vs 11 months, p=0.25). TTFT between two groups NOTCH1mut (ddPCR+/ARMS-PCR+) and NOTCH1mut (ddPCR+/ARMS-PCR-) was no statistically different (1 month vs 1 months, p=0.32).

We also found shorter TTFT in NOTCH1 group of CLL patients defined as mutated by both methods ddPCR and ARMS-PCR compared to NOTCH1 patients with the median 1 month vs 11 months, respectively (p=0.001) (Figure 3C). In addition, we showed that cohorts of patients with NOTCH1mut defined as positive only by ddPCR and patients with NOTCH1mut defined by both methods ddPCR and ARMS-PCR were tended to represented groups with worse prognosis and compared to group of NOTCH1wt CLL cohort with the median 1month vs 1 month vs 11 months, respectively (p=0.09).

Impact of the Mutational Status of NOTCH1 Combined with Mutational Status of IGHV on Clinical Outcome in CLL

In the entire cohort of CLL patients significantly longer TTFT in IGHV cases in which the median TTFT was not reached compared to IGHV with the median of 5 months was observed (p<0.0001) (Figure 4A).

Figure 4

Impact of the mutational status of IGHV and NOTCH1 on clinical outcome in CLL. (A) TTFT divided into two groups according to the IGHV mutational status: IGHVmut/IGHVum. TTFT was longer in IGHV cases in which the median was not reached during the follow-up compared to IGHV with a median of 5 months (p<0.0001). (B) TTFT divided into four groups according to the mutational status of IGHV combined with NOTCH1 assessed by ddPCR: NOTCH1mutIGHVmut, NOTCH1wtIGHVmut, NOTCH1. TTFT was significantly longer in IGHVmut cases who have also NOTCH1wt compared to those with harboring NOTCH1mut. The median TTFT was not reached during the follow-up in NOTCH1wtIGHVmut cases. The median for NOTCH1mutIGHVmut cases was 1 month. Among the IGHVum cases, the median was 1 month for NOTCH1mutIGHVum group and 2 months for NOTCH1wtIGHVum group. (C) TTFT divided into three groups according to the mutational status of IGHV combined with NOTCH1 assessed by ARMS-PCR: NOTCH1wtIGHVmut, NOTCH1mutIGHVum, NOTCH1wtIGHVum. The median was not reached during the follow-up in the NOTCH1wtIGHVmut group. The NOTCH1mutIGHVmut group involved only one patient. Among the IGHVum cases, the median TTFT was 2 months for NOTCH1mutIGHVum group and 4 months for NOTCH1wtIGHVum cases. (D) The median TTFT in a group with high NOTCH1mut allelic burden as well as low NOTCH1mut allelic burden tended to be shorter compared to the group with no NOTCH1wt for whom the median TTFT was not reached during the follow up (5.5 months vs 21.5 months, undefined; p=0.05). The TTFT was shorter in a group with high NOTCH1mut allelic burden compared to the group with no NOTCH1wt (5 months vs not reached, p=0.01). The TTFT was shorter in a group with low NOTCH1mut allelic burden compared to the group with no NOTCH1wt (2 months vs not reached, p=0.024). The TTFT was no different between the groups with high NOTCH1mut allelic burden and low NOTCH1mut allelic burden (5 months vs 2 months, p=0.901). The high mutation burden group was defined as having above 7.57% FA of NOTCH1ut. The low mutation burden group was defined as having below 7.57% FA of NOTCH1mut. No mutation burden group was defined as having below 0% FA of NOTCH1mut.

Next, patients were divided into four groups according to the mutational status of IGHV and NOTCH1 assessed by ddPCR: NOTCH1 (Figure 4B). From these four groups, we were able to discriminate a group with the most favorable prognosis: NOTCH1wtIGHVmut. We proved that among IGHV cases, TTFT was significantly longer in cases with NOTCH1wt (median TTFT n.r.) compared to those with harboring NOTCH1 (median TTFT = 1 month). Additionally, we showed that TTFT for NOTCH1 group was similar to patients with IGHV (median 1 month for NOTCH1 group and 2 months for NOTCH1wtIGHVum group).

Almost analogous analyses were performed to characterize the impact of the mutational status of IGHV combined with NOTCH1 determined by ARMS-PCR on clinical outcome in CLL (Figure 4C). Conclusions concerning the prognosis of the one case with NOTCH1mutIGHVmut cannot be overinterpreted. Finally, we performed univariate and multivariate analyses for TTFT in reference to the mutational status of IGHV and NOTCH1 assessed by ddPCR (Table 2). Multivariate analysis including IGHV and NOTCH1 defined by ddPCR in our cohort of CLL patients revealed that only IGHV unmutated status represented independent factor associated with shorter TTFT (HR, 2.64; 95%-CI, 1.42–4.91; p=0.002). While the mutational status of NOTCH1 defined by ddPCR constituted a dependent factor on the mutational status of IGHV (HR, 1.66; 95%-CI, 0.88–3.13; p=0.117).

Table 2

Univariate and Multivariate Analyses of TTFT in CLL Patients

Variable			Univariate			Multivariate
	N	Events	HR	95% CI	p	HR	95% CI	p
IGHV unmut vs mut	86	46	2.55	(1.31–4.74)	0.003	2.64	(1.42–4.91)	0.002
NOTCH1 mut vs unmut (ddPCR)	86	46	1.74	(0.91–3.32)	0.095	1.66	(0.88–3.13)	0.117

Prognostic Value of the NOTCH1mut Allelic Burden

To define the prognostic significance of NOTCH1mut allelic burden, we analyzed Kaplan–Meier curves for groups with high, low and no NOTCH1mut allelic burden defined as a frequency of fractional abundance (FA%) obtained in the ddPCR analysis. FA denotes the proportion of the mutant allele frequencies assessed by the program using in ddPCR, ie, QuantaSoft v1.7.4. Software. FA was calculated as a formula: FA = absolute quantification of mutant clone/absolute quantification of mutant clone + wild type clones. Data were dichotomized according to the median NOTCH1mut allelic burden in NOTCH1mut group of CLL patients with the cut off 7.57% FA. We found that the median TTFT in group with high NOTCH1mut allelic burden as well as low NOTCH1mut allelic burden was shorter compared to the group with no NOTCH1mut (NOTCH1) allelic burden for whom the median TTFT was not reached during the follow up (5 months vs 2 months, undefined, p=0.02 (Figure 4D).

The Characterization of NOTCH1 Allelic Burden in Different Prognostic Groups of CLL

Owing to the ddPCR method we found a higher NOTCH1mut allelic burden in a CD38+ group compared to CD38- with the median allelic burden 0.0370 vs 0.0120 (p=0.02). In accordance with increased NOTCH1mut allelic burden in ZAP-70+ group compared to ZAP-70- with the median allelic burden 0.0330 vs 0.009 (p=0.01) was demonstrated.

Analogous analysis in the cohort of only NOTCH1 samples defined by ddPCR showed a tendency to higher NOTCH1mut allelic burden in CD38+ group compared to CD38- (29.1 vs 3.28, p=0.10). However, there were no statistically significant differences in NOTCH1 mutation allelic burden in a ZAP-70+ group compared to ZAP-70- (28.30 vs 5.67, p=0.381).

Interestingly, NOTCH1 allelic burden tends to be elevated in male patients compared to female patients with the median allelic burden 0.0210 vs 0.009 (p=0.09). We did not observe any differences in NOTCH1mut allelic burden in reference to mutation status of IGHV (p=0.586), TP53 (p=0.11), MYD88 (p=0.270), SF3B1 (p=0.469). We did not find any differences in NOTCH1mut allelic burden in patients with 17p or/and 11q deletion compared to other patients (p=0.966). We did not find any association between NOTCH1t allelic burden with the Rai stage (p=0.324), age (p=0.520), serum level of β2microglobulin (p=0.208), and activity of lactate dehydrogenase (LDH) (p=0.107). The analysis revealed no differences in NOTCH1mut allelic burden between a group of patients with stereotyped subsets associated with negative prognosis including #1, #2, #8 and other subsets (p=0.473).

Discussion

The prognostic role of NOTCH1 has been investigated during the last few years.10,12,21,26,27 There was evidence that patients at progression as well as relapse, had more frequently NOTCH1mut.8,10,21 It was confirmed that NOTCH1mut was predominantly clonal in advanced CLL. Thereby NOTCH1mut has been considered as an early molecular event in the clonal evolution of CLL.28

The association of NOTCH1 with shorter OS and shorter TTFT in CLL proved in many studies10,11,18,22,27 while others cannot reach its statistical significance.15,29,30 The TTFT is a clinically validated endpoint for treatment-naive CLL patients reflecting in a more appreciated way the intrinsic biological complexity of the disease independently on the efficacy of treatment, treatment-induced clonal evolution as well as disease-related and unrelated deaths. Identifying the association between TTFT and some marker might help to identify early drivers in leukemogenesis and progression.31,32

Several studies8,10,18,33 revealed that NOTCH1mut was detected in about 8–10% of CLL patients at diagnosis using ARMS-PCR. Minervini et al22 also found a higher incidence of NOTCH1mut using ddPCR compared to (allele-specific PCR) AS-PCR in a small cohort of CLL patients (53.4% vs 37.5%). This discrepancy with our results might be explained mainly by the different limits of detection of the ddPCR assay as well as may reflect distinct clinical features of the study group of CLL patients. Minervini et al22 defined the limit of detection of the ddPCR assay as FA>0.03%, while we calculated the limit of detection as FA>0.06%. Moreover, Hoofd et al34 using ddPCR showed the high frequency of NOTCH1mut in a group of unselected CLL patients with the highest onset in a group of patients with trisomy 12.

In survival analyses, we revealed significantly shorter median TTFT in the NOTCH1mut group of patients compared to the NOTCH1wt defined by ddPCR. Moreover, in our cohort of patients, ARMS-PCR was not able to provide a significant difference in TTFT in NOTCH1mut group of patients vs NOTCH1wt although the difference was of 3.5 months vs 25 months. No significant difference in TTFT between two groups NOTCH1mut detected by ddPCR and not by ARMS-PCR compared to NOTCH1wt group (1 month vs 11 months, p=0.25) might be a consequence of the limitations of the current paper that are associated with the retrospective design of the study, patient selection due to use of available samples as well as the limited number of events. Moreover, in survival analyses, we showed also that TTFT is shorter in cases defined as a positive for the detection NOTCH1mut by both methods: ddPCR and ARMS-PCR compared to those without mutation NOTCH1wt (1 month vs 11 months, p=0.001). Hence, our results might suggest that detection of NOTCH1mut by ddPCR could allow predicting a group of patients with an unfavorable prognosis at an earlier stage of the disease. Interestingly, differentiation of survival curves revealed that at 24 months all of the patients from the cohort defined as mutated using ddPCR and ARMS-PCR have initiated the treatment. Whereas in the cohort defined as mutated by ddPCR only above 20% patients remained untreated, what might suggest that the allelic burden of NOTCH1mut tends to have prognostic value as ARMS-PCR have low sensitivity and detects mutation only in patients with high level of NOTCH1. We observed that in addition to a group of patients with high NOTCH1t allelic burden also a group with low NOTCH1 allelic burden have a worse prognosis than a group with NOTCH1wt. Thereby we might suggest the importance of NOTCH1 assessment using ddPCR as a quantitative method in CLL patients in predicting the outcome.

Interestingly, Lionetti et al35 using ultra-deep NGS with high sensitivity for the detection of small mutated subclones represented in 1% of the tumor cell population, revealed the occurrence of NOTCH1 in a considerable cohort of patients with monoclonal B cell lymphocytosis (MBL) or early clinical stage of CLL. They proved that NOTCH1 occurred in 11% of monoclonal B cell lymphocytosis (MBL) as well as in 13.4% CLL cases with Binet stage A. Moreover, they found that NOTCH1 mutational burden generally tends to be stable over time in NOTCH1 group of patients, and this did not appear during disease progression.35 Interestingly, Raponi et al36 analyzed the occurrence of NOTCH1 in 20 ultra-stable CLL (US-CLL) patients characterized as a group of patients with no progression for over 10 years from the time of diagnosis. Using whole-exome sequencing (WES) analyses, they detected no clonal mutations of NOTCH1 in US-CLL. Additionally, Amin et al37 showed that NOTCH1mut was already clonal before the therapy indicating the pretreatment driver role in the pathogenesis of CLL. Similarly other studies indicated that the acquisition of mutation during the CLL evolution is uncommon.7,14,21 Although in cases progressing to Richter Syndrome or chemorefractory CLL NOTCH1mut allelic burden was found to not be stable during the disease course.8,10 In addition, Minervini et al22 observed that NOTCH1mut allelic burden was reduced significantly after therapy.

Taking into consideration rather stable mutational burden of NOTCH1 during the disease course of CLL, we provide the significant role of ddPCR analysis including qualitative and quantitative of NOTCH1 mutational status at the time of diagnosis to discriminate group of patients with low NOTCH1mut allelic burden that cannot be detected as a mutant by conventional ARMS-PCR. Further results obtained by Sportoletti et al18 showed that new high-sensitivity AS-PCR represents a valid tool for prognostic screening in CLL with higher sensitivity (0.1%) than direct Sanger Sequencing (10%). They observed that sequential samples derived from three patients became positive by both methods during the progression of the disease, suggesting that subclonal NOTCH1 mutation was progressively selected to a clonal level. Authors also proved that NOTCH1mut cases defined as positive only by the AS-PCR have shorter OS than NOTCH1wt.

Despite the great sensitivity, ddPCR detects only the c.7541–7542celCT point mutation, missing all other coding and 3ʹUTR mutations in contrast to time-consuming method of the NGS sequencing.38 In the latest NGS analysis, Hu et al27 correlated 29 somatic mutations including NOTCH1, IGHV, TP53 with TTFT in treatment-naive CLL patients and proved at univariable analyses shorter TTFT referring to NOTCH1mutIGHVum. They suggested that IGHVum, as well as NOTCH1mut might be of particular importance in early disease progression in contrast to TP53mut.

The International prognostic score (IPS-E) for TTFT prediction of asymptomatic early-stage chronic lymphocytic leukemia includes the analysis of the mutational status of IGHV genes. Patients with mutated IGHV have a favorable prognosis in contrast to patients with unmutated IGHV with unfavorable prognosis.39 In our study, survival analysis enables to discriminate a group with the most favorable prognosis: NOTCH1wtIGHVmut. We proved that TTFT for NOTCH1wtIGHVmut group was significantly longer compared to NOTCH1mutIGHVmut. Moreover, the prognosis of NOTCH1mutIGHVmut group was similar to IGHV cases including NOTCH1mutIGHVumNOTCH1wtIGHVum. Analogical analyses with the use of ARMS-PCR did not show such differences in TTFT and analysis of NOTCH1 mutation did not improve IGHV-based stratification. Thereby we indicate that the selection of the precise method of NOTCH1mut detection as ddPCR and assessment of IGHV might be relevant to more accurate discrimination of prognostic groups of CLL patients, especially those harboring NOTCH1mut irrespective of the quantity of allelic burden.

In conclusion, ddPCR provides higher sensitivity in NOTCH1mut detection in CLL. Application of ddPCR for patients with CLL at the time of diagnosis might enable earlier identification of a group of patients harboring a low burden of NOTCH1mut associated with a worse prognosis. Analysis of the mutational status of IGHV combined with NOTCH1 assessed by ddPCR could discriminate group with the best prognosis: IGHVmutNOTCH1wt.

Our data suggest the relevance of using a very sensitive method of ddPCR to detect NOTCH1mut to improve prognostic stratification of CLL patients, especially newly diagnosed and treatment naïve CLL patients. Consequently, the cooperation molecular markers with the clinical features might appoint treatment decisions and thereby applicate precision medicine in the treatment algorithm of CLL.40